One can assume that EV-contained cargo is a main determinant of the therapeutic efficacy of their application. As mention above, EVs may carry a great variety of biologically active molecules, including RNAs, proteins and lipids, which makes them a conveyor of virtually unlimited types of cargos. The cargo can be packed into EVs during their intracellular biogenesis or extracellularly after EVs’ exocytosis. The latter generally happens in in vitro conditions [
43], but some results suggest the possibility of loading of freely circulating RNAs into EVs also in vivo [
44]. Accordingly, the methods for loading EVs with selected molecules can be classified into two main groups, i.e., those based on modification of parental cells and those adapting physicochemical techniques enabling in vitro loading [
45].
Parental cells can be passively loaded with chosen molecules. Along these lines, human gingival mesenchymal stromal cells were shown to uptake the chemotherapeutic drugs during standard cell culture [
46]. Furthermore, one of these drugs, namely paclitaxel, was then found in cell-secreted EVs that expressed anti-cancer activity in vitro [
47]. Similar activity was observed in the case of paclitaxel-carrying EVs released by mouse mesenchymal stromal cells [
48]. In addition, mouse and human tumor cell lines were also shown to release drug-containing EVs after simple culturing in the presence of different chemotherapeutics [
49]. In such cases, one can speculate that the drug is passively packaged into EVs during their formation. On the other hand, EV-parental cells can be transfected or transduced by non-viral or viral vectors, respectively, to produce the encoded molecules. These would likely be then actively sorted into EVs during their biogenesis. Accordingly, parental cells transfected with different plasmids were shown to secrete EVs that contained the plasmid-encoded products, including antibody protein and mRNA for enzyme that activates the chemotherapeutic prodrug. As a result, EVs were able to deliver mRNA to the cells of HER2-positive human breast tumor xenografts in a targeted manner due to the surface-expressed anti-HER2 antibody, which inhibited the growth of the xenografts in mice [
50]. Interestingly, the later results suggested that EVs may deliver in vitro transcribed enzyme-encoding mRNA, which allows to eliminate the potentially harmful plasmid transfection of EV-parental cells [
51]. Another interesting possibility was proposed by Sancho-Albero et al. [
31]. The authors reported that hollow gold nanoparticles incubated with EV-parental cells are much more efficiently incorporated into EVs after their PEGylation. Delivery by EVs may greatly improve the accumulation of PEGylated gold nanoparticles in tumors [
31]. However, many variables have to be taken into account while using these strategies. Therefore, at present, much more commonly used strategies are based on loading EVs with selected cargo after their isolation [
45]. Maintaining the EVs’ integrity, allowing to protect the incorporated cargo from extracellular degradation or inactivation, is one of the features that should be considered while choosing the loading method.
3.3. Directing EVs towards Desired Target
Loading EVs with selected cargo seems to be crucial for induction of expected biological effect. However, directing EVs towards desired target cells is likely the most important step to achieve the highest efficacy of EV-mediated therapeutic effect. Directed targeting greatly increases the dose of EVs that reach the desired cells and tissues and, simultaneously, limits the unwanted engulfment of EVs by other cells, including phagocytes.
Currently, some researchers attempt to genetically modify the parental cells to facilitate the selective tissue targeting by derived EVs. Along these lines, EVs generated by engineered immature DCs expressed membrane protein (Lamp2b) that was fused to αv integrin-specific iRGD peptide, which mediates tumor homing [
95]. Otherwise, EV-parental cells were transfected with plasmid containing cDNA sequence for anti-HER2 antibody single-chain variable fragment (scFv) of ML39 clone, which allowed generation of EVs that expressed the antibody. After in vivo administration into mice with implanted HER2-positive breast tumor, these directed EVs, additionally loaded with mRNA for enzyme that activates chemotherapeutic prodrug, were found most effective [
50]. In another study, AS1411 DNA aptamer that binds to nucleolin abundantly expressed on breast cancer cells was used as tumor targeting ligand. Its conjugation to cholesterol in EV membrane ensured selective, tumor cell-targeted EV action [
96]. Future perspectives in cell targeting may be based on interactions between receptors and ligands as well as on specific binding of antigen by antibodies.
3.4. Selecting the Optimal Route of EVs’ Administration
Depending on the route of administration, antigens may be either immunogenic or tolerogenic [
118]. Analogously, one can speculate that the route of EVs’ administration may either increase or diminish their eventual effect. Furthermore, it also determines the biodistribution and bioavailability of EVs as well as may facilitate their barrier-crossing ability. Thus, delivery route is one of the essential factors determining the overall efficiency of EVs’ therapeutic activity [
119]. On the other hand, route of therapeutic EVs’ administration should be accepted by patients.
So far, various routes of EVs’ administration have been experimentally examined. Some showed that intravenous route is more efficient than intraperitoneal injection [
120], and that intradermal application has an advantage over subcutaneous treatment [
121]. Interestingly, intravenously infused EVs were shown to co-localize with microglia in injured spinal cord of contused rats [
122]. Furthermore, intranasally administered EVs can be incorporated by neurons and microglia [
123]. Moreover, orally administered EVs from bovine milk were found to ameliorate arthritis in mice [
124]. Similarly, we have observed that EVs released by suppressor T cells from mice tolerized to casein, suppress casein-induced delayed-type hypersensitivity response after administration via intravenous, intraperitoneal, intradermal and oral routes into actively immunized mice [
41]. Several other studies also suggested the functional activity of EVs delivered via oral route [
125,
126]. Therefore, oral route of treatment seems to be promising approach, firstly due to its accessibility and well acceptance by patients, and secondly, as it is amenable for repetitions. However, EVs’ formulations and dosing protocols for oral treatment must be well established to avoid variability in therapeutic efficacy.
4. Conclusions
The goal of this review was to comprehensively discuss the knowledge on currently available methods as well as future perspectives in manipulating EVs for therapeutic applications with a special emphasis on cancer treatment. EVs’ biology and their clinical applications are tremendously complex research areas. We hope that this review provides some useful insights for possible strategies and innovation in EVs’ applications, while being aware of the virtually inexhaustible nature of the undertaken topic [
127]. Extracellular vesicle research can be compared to exploring a newly discovered cave. The deeper you enter the cave, the more new side corridors you will find for exploration.